Are Ethnicity and Duration of Natalizumab Exposure Risk Factors for JCV Infection?December 1, 2012Multiple Sclerosis
Physicians, Patients Differ in Weighing Benefits Versus Side Effects of MS TherapiesNovember 1, 2012Multiple Sclerosis
John DeLuca, PhD, Discusses the Assessment and Rehabilitation of Cognitive Impairment in Multiple SclerosisOctober 1, 2012Multiple Sclerosis
Anthony Reder, MD, Discusses a 21-Year Follow-Up Study of Patients Who Have Multiple SclerosisSeptember 1, 2012Multiple Sclerosis
New and Noteworthy Information—AugustAugust 1, 2012Alzheimer's & CognitionMovement DisordersMultiple SclerosisStrokeParkinson's Disease
Long-Term Data Indicate Interferon Beta-1b Reduces the Risk of Death for Patients With MSAugust 1, 2012Multiple Sclerosis
Interferon Beta May Not Reduce Disability Progression for Patients With MSAugust 1, 2012Multiple Sclerosis
Should Patients Continue Natalizumab Treatment After a Positive JCV Test?August 1, 2012Multiple Sclerosis
Cognitive Rehabilitation Improves Quality of Life in Patients With MSAugust 1, 2012Multiple Sclerosis
